UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
Kinase Fusion Gene:MAP2K5_PIAS1 |
Kinase Fusion Protein Summary |
Kinase Fusion gene summary |
Kinase Fusion partner gene information | Kinase Fusion gene name: MAP2K5_PIAS1 | KinaseFusionDB ID: KFG3324 | FusionGDB2.0 ID: KFG3324 | Hgene | Tgene | Gene symbol | MAP2K5 | PIAS1 | Gene ID | 5607 | 8554 | |
Gene name | mitogen-activated protein kinase kinase 5 | protein inhibitor of activated STAT 1 | ||||||||||
Synonyms | HsT17454|MAPKK5|MEK5|PRKMK5 | DDXBP1|GBP|GU/RH-II|ZMIZ3 | ||||||||||
Cytomap | 15q23 | 15q23 | ||||||||||
Type of gene | protein-coding | protein-coding | ||||||||||
Description | dual specificity mitogen-activated protein kinase kinase 5MAP kinase kinase 5MAP kinase kinase MEK5bMAPK/ERK kinase 5MAPKK 5MEK 5 | E3 SUMO-protein ligase PIAS1AR interacting proteinDEAD/H (Asp-Glu-Ala-Asp/His) box binding protein 1DEAD/H box-binding protein 1E3 SUMO-protein transferase PIAS1RNA helicase II-binding proteingu-binding proteinprotein inhibitor of activated STAT pr | ||||||||||
Modification date | 20240305 | 20240411 | ||||||||||
UniProtAcc | Q13163 | O75925 | ||||||||||
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000560591, ENST00000178640, ENST00000340972, ENST00000354498, ENST00000395476, | ENST00000249636, ENST00000545237, ENST00000567417, | |||||||||
Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: MAP2K5 [Title/Abstract] AND PIAS1 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | MAP2K5(67950952)-PIAS1(68434628), # samples:1 PIAS1(68379088)-MAP2K5(67984817), # samples:1 |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | PIAS1 | GO:0016925 | protein sumoylation | 18579533 |
Tgene | PIAS1 | GO:0033235 | positive regulation of protein sumoylation | 17696781|21965678 |
Kinase Fusion gene breakpoints across MAP2K5 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Kinase Fusion gene breakpoints across PIAS1 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
Kinase Fusion gene information. |
Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
ChimerDB4 | TCGA-BR-6564-11A | MAP2K5 | chr15 | 67950952 | PIAS1 | chr15 | 68434628 |
Top |
Kinase Fusion ORF Analysis |
Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:67950952/:68434628) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
MAP2K5 | PIAS1 |
FUNCTION: Acts as a scaffold for the formation of a ternary MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. Activation of this pathway appears to play a critical role in protecting cells from stress-induced apoptosis, neuronal survival and cardiac development and angiogenesis. {ECO:0000269|PubMed:7759517, ECO:0000269|PubMed:9384584}. | FUNCTION: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Sumoylates PML (at'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation. Plays a dynamic role in adipogenesis by promoting the SUMOylation and degradation of CEBPB (By similarity). Mediates the nuclear mobility and localization of MSX1 to the nuclear periphery, whereby MSX1 is brought into the proximity of target myoblast differentiation factor genes (By similarity). Also required for the binding of MSX1 to the core enhancer region in target gene promoter regions, independent of its sumolyation activity (By similarity). Capable of binding to the core enhancer region TAAT box in the MYOD1 gene promoter (By similarity). {ECO:0000250|UniProtKB:O88907, ECO:0000269|PubMed:14500712, ECO:0000269|PubMed:21965678}.; FUNCTION: (Microbial infection) Restricts Epstein-Barr virus (EBV) lytic replication by acting as an inhibitor for transcription factors involved in lytic gene expression (PubMed:29262325). The virus can use apoptotic caspases to antagonize PIAS1-mediated restriction and express its lytic genes (PubMed:29262325). {ECO:0000269|PubMed:29262325}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of MAP2K5_PIAS1 |
Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
MAP2K5 | Q13163 | human | MAPK7 | Q13164 | Y221 | HQyFMtEyVAtRWYR | Pkinase |
MAP2K5 | Q13163 | human | MAPK7 | Q13164 | T219 | AEHQyFMtEyVAtRW | Pkinase |
Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
Enriched GO biological processes of the phosphorylation target genes of the kinase |
Kinase | GOID | GO term | P.adjust |
MAP2K5 | ID | Description | 0.00e+00 |
MAP2K5 | GO:0034115 | negative regulation of heterotypic cell-cell adhesion | 7.63e-03 |
MAP2K5 | GO:0070587 | regulation of cell-cell adhesion involved in gastrulation | 7.63e-03 |
MAP2K5 | GO:0070586 | cell-cell adhesion involved in gastrulation | 7.63e-03 |
MAP2K5 | GO:0034616 | response to laminar fluid shear stress | 7.63e-03 |
MAP2K5 | GO:0070885 | negative regulation of calcineurin-NFAT signaling cascade | 7.63e-03 |
MAP2K5 | GO:0106057 | negative regulation of calcineurin-mediated signaling | 7.63e-03 |
MAP2K5 | GO:0036003 | positive regulation of transcription from RNA polymerase II promoter in response to stress | 7.63e-03 |
MAP2K5 | GO:0050849 | negative regulation of calcium-mediated signaling | 7.63e-03 |
MAP2K5 | GO:0071498 | cellular response to fluid shear stress | 7.63e-03 |
MAP2K5 | GO:0034114 | regulation of heterotypic cell-cell adhesion | 7.63e-03 |
MAP2K5 | GO:0043618 | regulation of transcription from RNA polymerase II promoter in response to stress | 7.63e-03 |
MAP2K5 | GO:0034405 | response to fluid shear stress | 7.63e-03 |
MAP2K5 | GO:1902176 | negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 7.63e-03 |
MAP2K5 | GO:1901099 | negative regulation of signal transduction in absence of ligand | 7.63e-03 |
MAP2K5 | GO:2001240 | negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 7.63e-03 |
MAP2K5 | GO:2000352 | negative regulation of endothelial cell apoptotic process | 7.63e-03 |
MAP2K5 | GO:0043620 | regulation of DNA-templated transcription in response to stress | 7.63e-03 |
MAP2K5 | GO:0070884 | regulation of calcineurin-NFAT signaling cascade | 7.63e-03 |
MAP2K5 | GO:0106056 | regulation of calcineurin-mediated signaling | 7.63e-03 |
MAP2K5 | GO:0033173 | calcineurin-NFAT signaling cascade | 7.63e-03 |
MAP2K5 | GO:1902175 | regulation of oxidative stress-induced intrinsic apoptotic signaling pathway | 7.63e-03 |
MAP2K5 | GO:2001239 | regulation of extrinsic apoptotic signaling pathway in absence of ligand | 7.63e-03 |
MAP2K5 | GO:0097720 | calcineurin-mediated signaling | 7.63e-03 |
MAP2K5 | GO:0019933 | cAMP-mediated signaling | 7.66e-03 |
MAP2K5 | GO:0034113 | heterotypic cell-cell adhesion | 7.66e-03 |
MAP2K5 | GO:2000351 | regulation of endothelial cell apoptotic process | 7.66e-03 |
MAP2K5 | GO:0008631 | intrinsic apoptotic signaling pathway in response to oxidative stress | 7.66e-03 |
MAP2K5 | GO:1904036 | negative regulation of epithelial cell apoptotic process | 7.66e-03 |
MAP2K5 | GO:0038034 | signal transduction in absence of ligand | 7.66e-03 |
MAP2K5 | GO:0070301 | cellular response to hydrogen peroxide | 7.66e-03 |
MAP2K5 | GO:0072577 | endothelial cell apoptotic process | 7.66e-03 |
MAP2K5 | GO:0097192 | extrinsic apoptotic signaling pathway in absence of ligand | 7.66e-03 |
MAP2K5 | GO:0019935 | cyclic-nucleotide-mediated signaling | 8.93e-03 |
MAP2K5 | GO:0050848 | regulation of calcium-mediated signaling | 8.93e-03 |
MAP2K5 | GO:0060761 | negative regulation of response to cytokine stimulus | 9.82e-03 |
MAP2K5 | GO:2001237 | negative regulation of extrinsic apoptotic signaling pathway | 9.98e-03 |
MAP2K5 | GO:0042542 | response to hydrogen peroxide | 9.98e-03 |
MAP2K5 | GO:1904035 | regulation of epithelial cell apoptotic process | 1.07e-02 |
MAP2K5 | GO:2001243 | negative regulation of intrinsic apoptotic signaling pathway | 1.07e-02 |
MAP2K5 | GO:1904019 | epithelial cell apoptotic process | 1.32e-02 |
MAP2K5 | GO:0034614 | cellular response to reactive oxygen species | 1.37e-02 |
MAP2K5 | GO:2001236 | regulation of extrinsic apoptotic signaling pathway | 1.38e-02 |
MAP2K5 | GO:0060759 | regulation of response to cytokine stimulus | 1.56e-02 |
MAP2K5 | GO:2001242 | regulation of intrinsic apoptotic signaling pathway | 1.56e-02 |
MAP2K5 | GO:0007369 | gastrulation | 1.56e-02 |
MAP2K5 | GO:0050728 | negative regulation of inflammatory response | 1.56e-02 |
MAP2K5 | GO:0000302 | response to reactive oxygen species | 1.56e-02 |
MAP2K5 | GO:0022408 | negative regulation of cell-cell adhesion | 1.56e-02 |
MAP2K5 | GO:0019722 | calcium-mediated signaling | 1.57e-02 |
Top |
Related Drugs to MAP2K5_PIAS1 |
Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Distribution of the number of studies mentioning MAP2K5-PIAS1 and kinase inhibitors the PubMed Abstract (04-01-2024) |
Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to MAP2K5_PIAS1 |
Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
MeSH ID | MeSH term |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
Clinical Trials from clinicaltrials.gov (06-17-2024) |
Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |